Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

SNWV vs ANIK vs NVCR vs LNTH vs HOLX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SNWV
SANUWAVE Health, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$143M
5Y Perf.-83.9%
ANIK
Anika Therapeutics, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$203M
5Y Perf.-54.8%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-75.0%
LNTH
Lantheus Holdings, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$5.92B
5Y Perf.+562.8%
HOLX
Hologic, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$16.97B
5Y Perf.+42.6%

SNWV vs ANIK vs NVCR vs LNTH vs HOLX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SNWV logoSNWV
ANIK logoANIK
NVCR logoNVCR
LNTH logoLNTH
HOLX logoHOLX
IndustryMedical - DevicesMedical - DevicesMedical - Instruments & SuppliesDrug Manufacturers - Specialty & GenericMedical - Instruments & Supplies
Market Cap$143M$203M$1.92B$5.92B$16.97B
Revenue (TTM)$41M$116M$674M$1.55B$4.13B
Net Income (TTM)$-7M$-11M$-173M$279M$544M
Gross Margin77.7%58.6%75.2%60.5%52.8%
Operating Margin16.6%-10.5%-27.2%18.8%17.5%
Forward P/E17.4x17.5x17.2x
Total Debt$25M$24M$290M$738K$2.63B
Cash & Equiv.$10M$57M$103M$359M$1.96B

SNWV vs ANIK vs NVCR vs LNTH vs HOLXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SNWV
ANIK
NVCR
LNTH
HOLX
StockMay 20May 26Return
SANUWAVE Health, In… (SNWV)10016.1-83.9%
Anika Therapeutics,… (ANIK)10045.2-54.8%
NovoCure Limited (NVCR)10025.0-75.0%
Lantheus Holdings, … (LNTH)100662.8+562.8%
Hologic, Inc. (HOLX)100142.6+42.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: SNWV vs ANIK vs NVCR vs LNTH vs HOLX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HOLX leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Lantheus Holdings, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. SNWV also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
SNWV
SANUWAVE Health, Inc.
The Growth Play

SNWV ranks third and is worth considering specifically for growth exposure.

  • Rev growth 60.0%, EPS growth 42.3%, 3Y rev CAGR 35.9%
  • 60.0% revenue growth vs ANIK's -5.9%
Best for: growth exposure
ANIK
Anika Therapeutics, Inc.
The Healthcare Pick

ANIK lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
NVCR
NovoCure Limited
The Healthcare Pick

Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.

Best for: healthcare exposure
LNTH
Lantheus Holdings, Inc.
The Long-Run Compounder

LNTH is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 41.9% 10Y total return vs HOLX's 124.3%
  • 18.0% margin vs NVCR's -25.7%
  • 12.4% ROA vs SNWV's -21.7%, ROIC 30.6% vs 159.8%
Best for: long-term compounding
HOLX
Hologic, Inc.
The Income Pick

HOLX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • beta 0.41
  • Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
  • Beta 0.41, current ratio 3.75x
  • Better valuation composite
Best for: income & stability and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthSNWV logoSNWV60.0% revenue growth vs ANIK's -5.9%
ValueHOLX logoHOLXBetter valuation composite
Quality / MarginsLNTH logoLNTH18.0% margin vs NVCR's -25.7%
Stability / SafetyHOLX logoHOLXBeta 0.41 vs NVCR's 2.20, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)HOLX logoHOLX+37.1% vs SNWV's -47.4%
Efficiency (ROA)LNTH logoLNTH12.4% ROA vs SNWV's -21.7%, ROIC 30.6% vs 159.8%

SNWV vs ANIK vs NVCR vs LNTH vs HOLX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SNWVSANUWAVE Health, Inc.
FY 2024
Consumables and Parts
65.4%$21M
System Revenue
34.5%$11M
License Fees and Other
0.1%$40,000
ANIKAnika Therapeutics, Inc.
FY 2023
Joint Preservation and Restoration
84.8%$55M
Non-Orthopedic
15.2%$10M
NVCRNovoCure Limited

Segment breakdown not available.

LNTHLantheus Holdings, Inc.
FY 2025
Product
33.4%$1.5B
Radiopharmaceutical Oncology
21.9%$989M
PYLARIFY
21.9%$989M
Total Precision Diagnostics
10.9%$493M
DEFINITY
7.3%$330M
Techne Lite
1.9%$87M
Strategic Partnerships And Other
1.3%$59M
Other (2)
1.3%$59M
HOLXHologic, Inc.
FY 2025
Diagnostics
44.6%$1.8B
Breast Health
36.2%$1.5B
Gyn Surgical
16.6%$680M
Skeletal Health
2.7%$109M

SNWV vs ANIK vs NVCR vs LNTH vs HOLX — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLSNWVLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

SNWV leads this category, winning 3 of 6 comparable metrics.

HOLX is the larger business by revenue, generating $4.1B annually — 100.0x SNWV's $41M. LNTH is the more profitable business, keeping 18.0% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, SNWV holds the edge at +22.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSNWV logoSNWVSANUWAVE Health, …ANIK logoANIKAnika Therapeutic…NVCR logoNVCRNovoCure LimitedLNTH logoLNTHLantheus Holdings…HOLX logoHOLXHologic, Inc.
RevenueTrailing 12 months$41M$116M$674M$1.5B$4.1B
EBITDAEarnings before interest/tax$8M-$7M-$165M$347M$974M
Net IncomeAfter-tax profit-$7M-$11M-$173M$279M$544M
Free Cash FlowCash after capex-$784,000$1M-$48M$372M$1000M
Gross MarginGross profit ÷ Revenue+77.7%+58.6%+75.2%+60.5%+52.8%
Operating MarginEBIT ÷ Revenue+16.6%-10.5%-27.2%+18.8%+17.5%
Net MarginNet income ÷ Revenue-17.1%-9.5%-25.7%+18.0%+13.2%
FCF MarginFCF ÷ Revenue-1.9%+0.9%-7.1%+24.0%+24.2%
Rev. Growth (YoY)Latest quarter vs prior year+22.3%+13.2%+12.3%+1.2%+2.5%
EPS Growth (YoY)Latest quarter vs prior year+117.4%-8.8%-100.0%+76.5%-9.2%
SNWV leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

ANIK leads this category, winning 3 of 6 comparable metrics.

At 26.7x trailing earnings, LNTH trades at a 13% valuation discount to HOLX's 30.5x P/E. On an enterprise value basis, LNTH's 14.6x EV/EBITDA is more attractive than SNWV's 24.1x.

MetricSNWV logoSNWVSANUWAVE Health, …ANIK logoANIKAnika Therapeutic…NVCR logoNVCRNovoCure LimitedLNTH logoLNTHLantheus Holdings…HOLX logoHOLXHologic, Inc.
Market CapShares × price$143M$203M$1.9B$5.9B$17.0B
Enterprise ValueMkt cap + debt − cash$158M$170M$2.1B$5.6B$17.6B
Trailing P/EPrice ÷ TTM EPS-2.37x-19.92x-13.80x26.69x30.53x
Forward P/EPrice ÷ next-FY EPS est.17.43x17.52x17.21x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple24.09x14.61x17.39x
Price / SalesMarket cap ÷ Revenue4.38x1.80x2.92x3.84x4.14x
Price / BookPrice ÷ Book value/share1.51x5.51x5.72x3.43x
Price / FCFMarket cap ÷ FCF72.67x46.51x16.73x18.44x
ANIK leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

LNTH leads this category, winning 7 of 9 comparable metrics.

LNTH delivers a 24.3% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-51 for NVCR. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), SNWV scores 7/9 vs LNTH's 5/9, reflecting strong financial health.

MetricSNWV logoSNWVSANUWAVE Health, …ANIK logoANIKAnika Therapeutic…NVCR logoNVCRNovoCure LimitedLNTH logoLNTHLantheus Holdings…HOLX logoHOLXHologic, Inc.
ROE (TTM)Return on equity-7.7%-50.8%+24.3%+11.0%
ROA (TTM)Return on assets-21.7%-5.9%-16.5%+12.4%+6.1%
ROICReturn on invested capital+159.8%-7.1%-16.4%+30.6%+9.4%
ROCEReturn on capital employed-6.4%-28.9%+17.1%+8.8%
Piotroski ScoreFundamental quality 0–976557
Debt / EquityFinancial leverage0.17x0.85x0.00x0.52x
Net DebtTotal debt minus cash$15M-$33M$187M-$358M$667M
Cash & Equiv.Liquid assets$10M$57M$103M$359M$2.0B
Total DebtShort + long-term debt$25M$24M$290M$738,000$2.6B
Interest CoverageEBIT ÷ Interest expense0.13x-96.80x11.72x8.00x
LNTH leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — SNWV and LNTH each lead in 2 of 6 comparable metrics.

A $10,000 investment in LNTH five years ago would be worth $41,420 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, HOLX leads with a +37.1% total return vs SNWV's -47.4%. The 3-year compound annual growth rate (CAGR) favors SNWV at 28.8% vs NVCR's -37.6% — a key indicator of consistent wealth creation.

MetricSNWV logoSNWVSANUWAVE Health, …ANIK logoANIKAnika Therapeutic…NVCR logoNVCRNovoCure LimitedLNTH logoLNTHLantheus Holdings…HOLX logoHOLXHologic, Inc.
YTD ReturnYear-to-date-42.4%+61.9%+28.3%+35.3%+1.9%
1-Year ReturnPast 12 months-47.4%+4.5%+1.1%+13.1%+37.1%
3-Year ReturnCumulative with dividends+113.5%-41.7%-75.7%-4.0%-8.5%
5-Year ReturnCumulative with dividends-72.2%-63.9%-91.3%+314.2%+15.8%
10-Year ReturnCumulative with dividends-20.7%-65.9%+30.3%+4192.5%+124.3%
CAGR (3Y)Annualised 3-year return+28.8%-16.5%-37.6%-1.4%-2.9%
Evenly matched — SNWV and LNTH each lead in 2 of 6 comparable metrics.

Risk & Volatility

HOLX leads this category, winning 2 of 2 comparable metrics.

HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs SNWV's 35.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSNWV logoSNWVSANUWAVE Health, …ANIK logoANIKAnika Therapeutic…NVCR logoNVCRNovoCure LimitedLNTH logoLNTHLantheus Holdings…HOLX logoHOLXHologic, Inc.
Beta (5Y)Sensitivity to S&P 5001.22x1.14x2.20x0.47x0.41x
52-Week HighHighest price in past year$46.59$16.24$20.06$93.00$76.04
52-Week LowLowest price in past year$15.36$7.87$9.82$47.25$52.81
% of 52W HighCurrent price vs 52-week peak+35.7%+93.2%+83.9%+97.8%+100.0%
RSI (14)Momentum oscillator 0–10034.253.369.861.269.1
Avg Volume (50D)Average daily shares traded84K135K1.5M886K10.0M
HOLX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: SNWV as "Buy", ANIK as "Buy", NVCR as "Buy", LNTH as "Buy", HOLX as "Hold". Consensus price targets imply 224.3% upside for SNWV (target: $54) vs 3.9% for HOLX (target: $79).

MetricSNWV logoSNWVSANUWAVE Health, …ANIK logoANIKAnika Therapeutic…NVCR logoNVCRNovoCure LimitedLNTH logoLNTHLantheus Holdings…HOLX logoHOLXHologic, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyHold
Price TargetConsensus 12-month target$54.00$33.50$101.00$79.00
# AnalystsCovering analysts26151742
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+4.7%0.0%+5.1%+4.4%
Insufficient data to determine a leader in this category.
Key Takeaway

SNWV leads in 1 of 6 categories (Income & Cash Flow). ANIK leads in 1 (Valuation Metrics). 1 tied.

Best OverallSANUWAVE Health, Inc. (SNWV)Leads 1 of 6 categories
Loading custom metrics...

SNWV vs ANIK vs NVCR vs LNTH vs HOLX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SNWV or ANIK or NVCR or LNTH or HOLX a better buy right now?

For growth investors, SANUWAVE Health, Inc.

(SNWV) is the stronger pick with 60. 0% revenue growth year-over-year, versus -5. 9% for Anika Therapeutics, Inc. (ANIK). Lantheus Holdings, Inc. (LNTH) offers the better valuation at 26. 7x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate SANUWAVE Health, Inc. (SNWV) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SNWV or ANIK or NVCR or LNTH or HOLX?

On trailing P/E, Lantheus Holdings, Inc.

(LNTH) is the cheapest at 26. 7x versus Hologic, Inc. at 30. 5x. On forward P/E, Hologic, Inc. is actually cheaper at 17. 2x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — SNWV or ANIK or NVCR or LNTH or HOLX?

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +314. 2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus ANIK's -65. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SNWV or ANIK or NVCR or LNTH or HOLX?

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 437% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

05

Which is growing faster — SNWV or ANIK or NVCR or LNTH or HOLX?

By revenue growth (latest reported year), SANUWAVE Health, Inc.

(SNWV) is pulling ahead at 60. 0% versus -5. 9% for Anika Therapeutics, Inc. (ANIK). On earnings-per-share growth, the picture is similar: Anika Therapeutics, Inc. grew EPS 80. 2% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, SNWV leads at 35. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SNWV or ANIK or NVCR or LNTH or HOLX?

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -96. 1% for SANUWAVE Health, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — SNWV leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SNWV or ANIK or NVCR or LNTH or HOLX more undervalued right now?

On forward earnings alone, Hologic, Inc.

(HOLX) trades at 17. 2x forward P/E versus 17. 5x for Lantheus Holdings, Inc. — 0. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNWV: 224. 3% to $54. 00.

08

Which pays a better dividend — SNWV or ANIK or NVCR or LNTH or HOLX?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is SNWV or ANIK or NVCR or LNTH or HOLX better for a retirement portfolio?

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SNWV and ANIK and NVCR and LNTH and HOLX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SNWV is a small-cap high-growth stock; ANIK is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SNWV

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Gross Margin > 46%
Run This Screen
Stocks Like

ANIK

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 35%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

LNTH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 10%
Run This Screen
Stocks Like

HOLX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SNWV and ANIK and NVCR and LNTH and HOLX on the metrics below

Revenue Growth>
%
(SNWV: 22.3% · ANIK: 13.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.